Multi-Omics-Based Phase Ⅱ Trial of Trastuzumab Rezetecan Plus Camrelizumab for Perioperative Therapy in HER2-Positive Muscle-Invasive Urothelial Carcinoma

Clinical trial NCT07639983 · NOT_YET_RECRUITING

Trial details

NCT number: NCT07639983
Sponsor: Sheng Tai
Status: NOT_YET_RECRUITING
Phase: Phase 2
Study type: INTERVENTIONAL

Muscle-Invasive Bladder Cancer (MIBC)Urinary Bladder Cancer

Start date: 2026-06-05
Primary completion: 2028-06-05
Enrollment: 44

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.